Emphasis on Product (Glucagon-like Peptide-2 (GLP2), Growth Hormone, Glutamine, Others); Distribution Channel (Hospitals Pharmacies, Retail pharmacies, Online Sales); Region/Country
The short bowel syndrome market is expected to register a CAGR of around 27% over the period of 2021-2027. Short bowel syndrome (SBS) is a metabolic disorder caused by dysfunction or elimination of the small intestine due to surgery for gastrointestinal disorders. The side effects of this syndrome include malabsorption, diarrhea, steatorrhea, water and electrolyte imbalances, and malnutrition. Initial treatment for short bowel syndrome includes maintaining good nutrition, maximizing the absorption area of the remaining intestine, and avoiding complications. The growing number of cases of short bowel syndrome is mainly due to an increase in diseases related to the intestine, genetic inheritance of SBS, etc. For instance, according to the National Institute of Diabetes and Digestive & Kidney Diseases, every year, short bowel syndrome affects nearly 3 out of every million people. Furthermore, the short bowel syndrome market is also anticipated to grow on account of the growing healthcare expenditure, rapid improvements in the field of healthcare have increased awareness regarding this disease, and state government with nonprofit organizations provide special incentives to market players as it promotes research & development related to short bowel syndrome.
Takeda Pharmaceutical Company Limited, Merck KGaA, Zealand Pharma A/S, OxThera, VectivBio AG, 9 Meters Biopharma Inc., Nutrinia Ltd., Hanmi Pharm.Co., Ltd., Pharmascience, Inc., and Nestle are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.
Insights Presented in the Report
“Amongst Product, the Glucagon-like peptide-2 (GLP2) category accounted for the majority share in the market in 2020”
Based on product, the market is classified into glucagon-like peptide- 2 (GLP2), growth hormone, glutamine, and others. Amongst products, the GLP2 category accounted for a significant share of the market. The only GLP-2 analog available on the market for the treatment of short bowel syndrome is Gattex and Revestive. the increase in prescriptions for Gattex therapy contributes to the growth of the market.
“Among Distribution Channel, the Hospital Pharmacies is expected to witness highest CAGR during the forecast period”
Based on distribution channels, the market is categorized into hospital pharmacies, retail pharmacies, and online sales. Among these, the hospital pharmacies are expected to witness a considerable CAGR during the forecast period due to an increase in patients in hospital settings and rising implementation of therapy. Moreover, patient preference for affordable and more expensive parenteral nutrition along with prescription drugs contributes to a large share of this segment.
“North America to witness significant growth during the forecast period”
For a better understanding of the market dynamics of the short bowel syndrome market, a detailed analysis was conducted for different regions across the globe including North America (the U.S, Canada, and the Rest of North America), Europe (Germany, France, Spain, United Kingdom, Italy, and Rest of Europe), Asia-Pacific (China, India, Australia, Japan, and Rest of APAC), Rest of World has been conducted. North America constitutes a major market for the short bowel syndrome in 2020 owing to due to the revenue generated by Gattex, the only glucagon-like peptide-2 (GLP-2) analog approved that improves intestinal absorption in patients with SBS in the U.S.
Reasons to buy this report:
Customization Options:
Global short bowel syndrome market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.
1. Market Introduction
2. Research Methodology Or Assumption
3. Market Synopsis
4. Executive Summary
5. Global Short Bowel Syndrome Market Covid-19 Impact
6. Global Short Bowel Syndrome Market Revenue, 2019-2027f
7. Market Insights By Product
8. Market Insights By Distribution Channel
9. Market Insights By Region
10. Short Bowel Syndrome Market Dynamics
11. Short Bowel Syndrome Market Opportunities
12. Short Bowel Syndrome Market Trends
13. Legal & Regulatory Framework
14. Demand And Supply Side Analysis
15. Value Chain Analysis
16. Competitive Scenario
17. Company Profiled
18. Disclaimer
Research Methodology for the Global Short Bowel Syndrome Market Analysis (2021-2027)
Analyzing the historical market, estimation of the current market, and forecasting the future market of the global short bowel syndrome market were the three major steps undertaken to create and analyze the adoption of short bowel syndrome in major regions globally. Exhaustive secondary research was conducted to collect the historical market numbers and estimate the current market size. Secondly, to validate these insights, numerous findings and assumptions were taken into consideration. Moreover, exhaustive primary interviews were also conducted, with industry experts across the value chain of the global short bowel syndrome market. Post assumption and validation of market numbers through primary interviews, we employed a top-down/bottom-up approach to forecasting the complete market size. Thereafter, market breakdown and data triangulation methods were adopted to estimate and analyze the market size of segments and sub-segments the industry pertains to. Detailed methodology is explained below:
Seek More Details About Research Methodology
Analysis of Historical Market Size
Step 1: In-Depth Study of Secondary Sources:
Detail secondary study was conducted to obtain the historical market size of the short bowel syndrome market through company internal sources such as annual report & financial statements, performance presentations, press releases, etc., and external sources including journals, news & articles, government publications, competitor publications, sector reports, third-party database, and other credible publications.
Step 2: Market Segmentation:
After obtaining the historical market size of the short bowel syndrome market, we conducted a detailed secondary analysis to gather historical market insights and share for different segments & sub-segments for major regions. Major segments included in the report as product and distribution types. Further country-level analyses were conducted to evaluate the overall adoption of testing models in that region.
Step 3: Factor Analysis:
After acquiring the historical market size of different segments and sub-segments, we conducted a detailed factor analysis to estimate the current market size of the short bowel syndrome market. Further, we conducted factor analysis using dependent and independent variables such as various products and distribution types of short bowel syndrome. A thorough analysis was conducted for demand and supply-side scenarios considering top partnerships, merger and acquisition, business expansion, and product launches in the Short bowel syndrome market sector across the globe.
Current Market Size Estimate & Forecast
Current Market Sizing: Based on actionable insights from the above 3 steps, we arrived at the current market size, key players in the global short bowel syndrome market, and market shares of the segments. All the required percentage shares split, and market breakdowns were determined using the above-mentioned secondary approach and were verified through primary interviews.
Estimation & Forecasting: For market estimation and forecast, weights were assigned to different factors including drivers & trends, restraints, and opportunities available for the stakeholders. After analyzing these factors, relevant forecasting techniques i.e., top-down/bottom-up approach was applied to arrive at the market forecast about 2027 for different segments and sub-segments across the major markets globally. The research methodology adopted to estimate the market size encompasses:
Market Size and Share Validation
Primary Research: In-depth interviews were conducted with the Key Opinion Leaders (KOLs) including Top Level Executives (CXO/VPs, Sales Head, Marketing Head, Operational Head, and Regional Head, Country Head, etc.) across major regions. Primary research findings were then summarized, and statistical analysis was performed to prove the stated hypothesis. Inputs from primary research were consolidated with secondary findings, hence turning information into actionable insights.
Split of Primary Participants in Different Regions
Market Engineering
Data triangulation technique was employed to complete the overall market estimation and to arrive at precise statistical numbers of each segment and sub-segment of the global short bowel syndrome market. Data was split into several segments & sub-segments post studying various parameters and trends in the areas of product and distribution type in the global short bowel syndrome market.
The main objective of the Global Short Bowel Syndrome Market Study
The current & future market trends of the global short bowel syndrome market were pinpointed in the study. Investors can gain strategic insights to base their discretion for investments on the qualitative and quantitative analysis performed in the study. Current and future market trends determined the overall attractiveness of the market at a regional level, providing a platform for the industrial participant to exploit the untapped market to benefit from a first-mover advantage. Other quantitative goals of the studies include:
Customers who bought this item also bought
Antibiotic Resistance Market: Current Analysis and Forecast (2024-2032)
Emphasis on Disease Type (Urinary Tract Infections, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections, And Others); Pathogen Type (Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae, and Others); Drug Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines, and Others); and Region/Country
October 8, 2024
